加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.4475
−US$0.02 · -4.28%
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
收盘时
US$0.4475
−US$0.02 · -4.28%
盘后
US$0.464
+US$0.0165 · +3.69%
10月12日 18:25 ET
盘中时间采用ET。市场数据可能有所延迟。
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
日内区间
当前US$0.4475
52周区间
当前US$0.4475
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
55
合理估值
情绪
58
多空交织
风险
66
高风险
动量
18
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
日内区间
当前US$0.4475
52周区间
当前US$0.4475
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 1.51万 USD |
| 销货成本 | — | — | — | 5094 USD | 1.73万 USD |
| 毛利 | — | — | — | −5094 USD | −2213 USD |
| 研究与开发 | 798.11万 USD | 719.85万 USD | 810.08万 USD | 266.54万 USD | — |
| 销售、一般及管理费用 | 1287.62万 USD | 705.15万 USD | 787.86万 USD | 991.85万 USD | 450.52万 USD |
| 营业费用 | 2085.73万 USD | 1425万 USD | 1597.94万 USD | 1258.39万 USD | 450.52万 USD |
| 利息收入 | 32.72万 USD | 42.32万 USD | 41.54万 USD | — | — |
| 利息支出 | — | — | — | 102 USD | 508 USD |
| 折旧和摊销 | 66.26万 USD | 64.9万 USD | 64.85万 USD | 5094 USD | 1379 USD |
| 营业利润 | −2085.73万 USD | −1425万 USD | −1597.94万 USD | −1258.9万 USD | −450.74万 USD |
| 净利润 | −2042.77万 USD | −1390.46万 USD | −1596.17万 USD | −1393.65万 USD | −217.35万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.00
上涨空间 570.39%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年1月2日 | 1:20 | — | — |
已生效 2024年1月2日
1:20
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
